

Raiffeisen Health and Wellbeing ESG Equities

(Original German name: Raiffeisen-Health and Wellbeing-ESG-Aktien)

semi-annual fund report

reporting period Jun 1, 2023 – Nov 30, 2023

Table of contents

General fund information	3
Fund characteristics.....	3
Legal notice	4
Fund details.....	5
Units in circulation.....	5
Fund investment policy report	6
Makeup of fund assets in EUR	7
Portfolio of investments in EUR as of Nov 30, 2023.....	8
Appendix	13

Report for the reporting period from Jun 1, 2023 to Nov 30, 2023

General fund information

ISIN	Tranche	Income class	Currency	Launch date
AT0000714274	Raiffeisen Health and Wellbeing ESG Equities (R) A	income-distributing	EUR	Apr 18, 2001
AT0000A1U651	Raiffeisen Health and Wellbeing ESG Equities (RZ) A	income-distributing	EUR	Apr 3, 2017
AT0000714282	Raiffeisen Health and Wellbeing ESG Equities (R) T	income-retaining	EUR	Apr 18, 2001
AT0000A1U644	Raiffeisen Health and Wellbeing ESG Equities (RZ) T	income-retaining	EUR	Apr 3, 2017
AT0000A2XN33	Raiffeisen Health and Wellbeing ESG Equities (SZ) T ¹	income-retaining	EUR	Jun 1, 2022
AT0000A2R8Q2	Raiffeisen Health and Wellbeing ESG Equities (I) VTA	full income-retaining (outside Austria)	EUR	Jun 1, 2021
AT0000712716	Raiffeisen Health and Wellbeing ESG Equities (R) VTA	full income-retaining (outside Austria)	EUR	Oct 29, 2002

¹ Tranche SZ is exclusively for investments within the scope of the Raiffeisen Banking Group's sustainable asset management.

Fund characteristics

Fund currency	EUR
Financial year	Jun 1 – May 31
Distribution/payment/reinvestment date	Aug 16
Type of fund	Investment fund pursuant to § 2 of the Austrian Investment Fund Act, InvFG (UCITS)
Effective management fee for the fund	I-Tranche (EUR): 1.000 % R-Tranche (EUR): 2.000 % RZ-Tranche (EUR): 1.000 % SZ-Tranche (EUR): 0.650 %
Custodian bank	Raiffeisen Bank International AG
Management company	Raiffeisen Kapitalanlage-Gesellschaft m.b.H. Mooslackengasse 12, A-1190 Vienna Tel. +43 1 71170-0 Fax +43 1 71170-761092 www.rcm.at Companies register number: 83517 w
Fund management	Raiffeisen Kapitalanlage-Gesellschaft m.b.H.
Auditor	KPMG Austria GmbH

The fund is actively managed without reference to a benchmark.

Legal notice

The software used performs calculations on the basis of more than the two decimal places displayed. Minor discrepancies cannot be ruled out due to further calculations using published results.

The value of a unit is calculated by dividing the entire value of the investment fund inclusive of its income by the number of units. The total value of the investment fund is calculated on the basis of the current market prices of the securities, money market instruments and subscription rights in the fund plus the value of the fund's financial investments, cash holdings, credit balances, receivables and other rights net of its payables. That value will be calculated by the custodian bank.

The net assets are calculated in accordance with the following principles:

- a) The value of assets quoted or traded on a stock exchange or other regulated market shall be determined, in principle, on the basis of the most recently available price.
- b) Where an asset is not quoted or traded on a stock market or another regulated market or where the price for an asset quoted or traded on a stock market or another regulated market does not appropriately reflect its actual market value, the prices provided by reliable data providers or, alternatively, market prices for equivalent securities or other recognized market valuation methods shall be used.

The performance is calculated by Raiffeisen KAG on the basis of published fund prices, using the method developed by OeKB (Österreichische Kontrollbank AG). Individual costs such as transaction fees, the subscription fee, the redemption fee, the custody charges of the investor and taxes are not included in the performance calculation. If included, these would lead to a lower performance. Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. Based on the illustration, you can assess how the fund was managed in the past.

Dear unitholder,

Raiffeisen Kapitalanlage-Gesellschaft m.b.H. is pleased to present its semi-annual fund report for Raiffeisen Health and Wellbeing ESG Equities for the reporting period from Jun 1, 2023 to Nov 30, 2023. The accounting is based on the price calculation as of Nov 30, 2023.

Fund details

	May 31, 2023	Nov 30, 2023
Total fund assets in EUR	203,887,803.58	198,574,302.24
Net asset value/distributing units (R) (AT0000714274) in EUR	228.59	223.62
Issue price/distributing units (R) (AT0000714274) in EUR	228.59	223.62
Net asset value/distributing units (RZ) (AT0000A1U651) in EUR	138.50	136.19
Issue price/distributing units (RZ) (AT0000A1U651) in EUR	138.50	136.19
Net asset value/reinvested units (R) (AT0000714282) in EUR	280.35	277.21
Issue price/reinvested units (R) (AT0000714282) in EUR	280.35	277.21
Net asset value/reinvested units (RZ) (AT0000A1U644) in EUR	148.73	147.80
Issue price/reinvested units (RZ) (AT0000A1U644) in EUR	148.73	147.80
Net asset value/reinvested units (SZ) (AT0000A2XN33) in EUR	99.53	99.13
Issue price/reinvested units (SZ) (AT0000A2XN33) in EUR	99.53	99.13
Net asset value/fully reinvested units (I) (AT0000A2R8Q2) in EUR	109.99	109.31
Issue price/fully reinvested units (I) (AT0000A2R8Q2) in EUR	109.99	109.31
Net asset value/fully reinvested units (R) (AT0000712716) in EUR	296.31	293.00
Issue price/fully reinvested units (R) (AT0000712716) in EUR	296.31	293.00

Units in circulation

	Units in circulation on May 31, 2023	Sales	Repurchases	Units in circulation on Nov 30, 2023
AT0000714274 (R) A	69,836.243	1,666.518	-12,274.775	59,227.986
AT0000A1U651 (RZ) A	39,774.607	1,320.492	-1,780.132	39,314.967
AT0000714282 (R) T	354,131.758	28,905.558	-27,712.299	355,325.017
AT0000A1U644 (RZ) T	230,395.303	19,143.528	-14,804.535	234,734.296
AT0000A2XN33 (SZ) T	10.000	0.000	0.000	10.000
AT0000A2R8Q2 (I) VTA	10.000	0.000	0.000	10.000
AT0000712716 (R) VTA	164,904.368	15,510.029	-20,778.667	159,635.730
Total units in circulation				848,257.996

Fund investment policy report

In the period under review, the value of the fund declined by 0.69 %. In the first month of the reporting period, the stock markets recorded a very buoyant performance across the board after an agreement had been reached to raise the US debt ceiling. Volatility intensified towards late June 2023 as questions arose about the US medium-term interest rate policy. As a result, the global stock markets showed a tendency towards weakness, with mixed macro data and fears of further interest rate hikes putting pressure on investor sentiment. Even a constructive Q2 reporting season did nothing to change this. In a rather fragile macroeconomic environment, the healthcare sector failed to capitalize on its defensive qualities during the reporting period. Despite the fact that the average Q2 and Q3 figures exceeded expectations, this was mainly due to a significant double-digit decline in profits in the sector as a whole. Within the sector, pharmaceutical stocks still delivered the best performance, while medical technology stocks and especially the life science & diagnostics sector suffered from destocking and relatively weak demand (sharp decline in COVID-19 sales). The biotechnology sub-sector continued to face financing problems in the wake of rising interest rates. This was particularly true for small and mid-caps. However, the segment saw a significant increase in M&A activities. The big pharmaceutical companies, which stand to incur a substantial drop in sales around 2025/2026 when patents on important drugs expire, are trying to compensate for the lost revenues and profits through selective acquisitions targeting interesting indications and research areas. This trend is likely to continue for a good few months yet. The single most important topic in the reporting period was and remained “GLP-1”, the collective term for the “weight loss pen” developed by Novo Nordisk and Eli Lilly, which to date are the only manufacturers to hold a license for individual products. The research pipelines of various “follower” companies are well stocked, not least with regard to the oral administration version, which is far more user-friendly than the subcutaneous version. The well-being segment (water treatment, hygiene, safety technology, sporting goods and health food) is covered by industry, defensive and cyclical consumption, and utilities. In this area, the individual sectors followed rather different trends. Their share of the total fund was around 10 %. In the course of the half year, the shares of Getinge, Novartis, Sunopta, Vital Farms and Gerresheimer were added to the fund. In return, the shares of Baxter, Costa Group, Sartorius Stedim, Tandem Diabetes, Resmed, Systemex, Sonova, Sandoz, Veralto, Centene, Moderna and Waters were sold outright. On the reporting date, the fund included a total of 73 equity positions, with the biggest country weightings held by the USA, followed by Switzerland, Denmark and the UK. As regards the currencies, the euro gained around 1.2 % against US dollar, approx. 8.0 % against the Japanese yen, 0.4 % against the British pound and 0.1 % against the Danish crown, while dropping 2.2 % against the Swiss franc.

Makeup of fund assets in EUR

Any discrepancies in terms of the market value or the share of the fund assets result from rounding-off.

UCITS refers to units in an undertaking for collective investment in transferable securities

§ 166 InvFG refers to units in investment funds in the form of "other portfolios of assets"

§ 166 (1) item 2 InvFG refers to units in special funds

§ 166 (1) item 3 InvFG refers to units in undertakings for collective investment in transferable securities pursuant to § 166 (1) item 3 InvFG
(such as alternative investments/hedge funds)

§ 166 (1) item 4 InvFG refers to units in real estate funds

Type of security	OGAW/§ 166	Currency	Market value in EUR	Share of fund assets
Equities		AUD	2,531,040.72	1.27 %
Equities		CHF	15,428,378.04	7.77 %
Equities		DKK	13,789,176.50	6.94 %
Equities		EUR	19,021,765.24	9.58 %
Equities		GBP	10,910,987.71	5.49 %
Equities		JPY	4,480,311.07	2.26 %
Equities		SEK	4,327,553.56	2.18 %
Equities		USD	126,273,389.52	63.59 %
Total Equities			196,762,602.36	99.09 %
Equities ADR		USD	904,328.02	0.46 %
Total Equities ADR			904,328.02	0.46 %
Total securities			197,666,930.38	99.54 %
Bank balances/liabilities				
Bank balances/liabilities in fund currency			1,127,693.71	0.57 %
Total bank balances/liabilities			1,127,693.71	0.57 %
Accruals and deferrals				
Interest claims (on securities and bank balances)			9,229.82	0.00 %
Dividends receivable			132,802.14	0.07 %
Total accruals and deferrals			142,031.96	0.07 %
Other items				
Various fees			-362,353.81	-0.18 %
Total other items			-362,353.81	-0.18 %
Total fund assets			198,574,302.24	100.00 %

Portfolio of investments in EUR as of Nov 30, 2023

Dates indicated for securities refer to the issue and redemption dates. An issuer's right of premature redemption (where applicable) is not specified.

The securities marked with a "Y" have an open-ended maturity (is perpetual). The price for forward exchange transactions is indicated in the relevant counter currency for the currency in question.

Any discrepancies in terms of the market value or the share of the fund assets result from rounding-off.

UCITS refers to units in an undertaking for collective investment in transferable securities

§ 166 InvFG refers to units in investment funds in the form of "other portfolios of assets"

§ 166 (1) item 2 InvFG refers to units in special funds

§ 166 (1) item 3 InvFG refers to units in undertakings for collective investment in transferable securities pursuant to § 166 (1) item 3 InvFG (such as alternative investments/hedge funds)

§ 166 (1) item 4 InvFG refers to units in real estate funds

Type of security	OGAW/§ 166	ISIN	Security title	Currency	Volume Units/Nom.	Purchases In period under review Units/Nom.	Sales	Pool-/ILB Factor	Price	Market value in EUR	Share of fund assets
Equities		AU000000CSL8	CSL LTD CSL	AUD	16,000	4,000			262.200000	2,531,040.72	1.27 %
Equities		CH0432492467	ALCON INC ALC	CHF	31,000	1,000	2,000		65.420000	2,111,970.84	1.06 %
Equities		CH0030170408	GEBERIT AG-REG GEBN	CHF	2,600		400		486.400000	1,316,990.37	0.66 %
Equities		CH0013841017	LONZA GROUP AG-REG LONN	CHF	5,800	1,900			341.800000	2,064,504.04	1.04 %
Equities		CH0012005267	NOVARTIS AG-REG NOVN	CHF	40,000	40,000			84.840000	3,534,079.67	1.78 %
Equities		CH0012032048	ROCHE HOLDING AG-GENUSSCHEIN ROG	CHF	26,000	5,000	5,912		236.400000	6,400,833.12	3.22 %
Equities		DK0061802139	ALK-ABELLO A/S ALKB	DKK	220,000	156,000	51,000		94.650000	2,792,784.33	1.41 %
Equities		DK0010272202	GENMAB A/S GMAB	DKK	4,000	754			2,142.000000	1,149,141.63	0.58 %
Equities		DK0062498333	NOVO NORDISK A/S-B NOVOB	DKK	106,500	108,000	1,500		689.400000	9,847,250.54	4.96 %
Equities		NL0011872650	BASIC-FIT NV BFIT	EUR	40,000				26.480000	1,059,200.00	0.53 %
Equities		FR0006174348	BUREAU VERITAS SA BVI	EUR	56,084		8,916		22.470000	1,260,207.48	0.63 %
Equities		FR0000121667	ESSILORLUXOTTICA EL	EUR	10,000				177.240000	1,772,400.00	0.89 %
Equities		DE0005664809	EVOTEC SE EVT	EUR	70,000				18.330000	1,283,100.00	0.65 %
Equities		DE000A0LD6E6	GERRESHEIMER AG GXI	EUR	18,000	18,000			87.700000	1,578,600.00	0.79 %
Equities		ES0171996095	GRIFOLS SA - B GRF/P	EUR	350,000		4,931		8.745000	3,060,750.00	1.54 %
Equities		DE0006599905	MERCK KGAA MRK	EUR	10,000		5,000		160.400000	1,604,000.00	0.81 %
Equities		NL0012169213	QIAGEN N.V. QIA	EUR	28,693	7,200			37.630000	1,079,717.59	0.54 %
Equities		FR0000120578	SANOFI SAN	EUR	44,000	3,600	5,600		84.870000	3,734,280.00	1.88 %
Equities		IT0005162406	TECHNOGYM SPA TGYM	EUR	159,261		40,739		7.970000	1,269,310.17	0.64 %
Equities		FR0000031577	VIRBAC SA VIRP	EUR	4,600	1,100			287.000000	1,320,200.00	0.66 %
Equities		GB0009895292	ASTRAZENECA PLC AZN	GBP	58,400	7,400			100.320000	6,778,143.11	3.41 %
Equities		GB00BN7SWP63	GSK PLC GSK	GBP	160,223				14.010000	2,597,008.42	1.31 %
Equities		GB00B39J2M42	UNITED UTILITIES GROUP PLC UU/	GBP	118,000		22,000		11.250000	1,535,836.18	0.77 %
Equities		JP3942400007	ASTELLAS PHARMA INC 4503	JPY	88,000	2,300			1,788.000000	972,664.22	0.49 %
Equities		JP3475350009	DAIICHI SANKYO CO LTD 4568	JPY	93,000	5,000			3,932.000000	2,260,524.46	1.14 %
Equities		JP3270000007	KURITA WATER INDUSTRIES LTD 6370	JPY	38,000		15,000		5,309.000000	1,247,122.39	0.63 %
Equities		SE0000382335	AUTOLIV INC-SWED DEP RECEIPT ALIV	SEK	16,000		8,000		1,071.000000	1,507,787.07	0.76 %
Equities		SE0009922164	ESSITY AKTIEBOLAG-B ESSITYB	SEK	57,343		11,657		263.400000	1,329,005.38	0.67 %
Equities		SE0000202624	GETINGE AB-B SHS GETIB	SEK	75,000	75,000			225.900000	1,490,761.11	0.75 %

reporting period Jun 1, 2023 – Nov 30, 2023

Raiffeisen Health and Wellbeing ESG Equities

Type of security	OGAW/§ 166	ISIN	Security title	Currency	Volume Units/Nom.	Purchases In period under review Units/Nom.	Sales	Pool-/ILB Factor	Price	Market value in EUR	Share of fund assets
Equities		US0028241000	ABBOTT LABORATORIES ABT	USD	64,700				103.630000	6,109,212.76	3.08 %
Equities		US00287Y1091	ABBVIE INC ABBV	USD	33,042		4,300		138.500000	4,169,764.92	2.10 %
Equities		US00404A1097	ACADIA HEALTHCARE CO INC ACHC	USD	27,500				71.920000	1,802,095.67	0.91 %
Equities		US00846U1016	AGILENT TECHNOLOGIES INC A	USD	16,000		1,300		127.590000	1,860,082.00	0.94 %
Equities		US0162551016	ALIGN TECHNOLOGY INC ALGN	USD	4,000		2,800		216.480000	788,993.17	0.40 %
Equities		US0304201033	AMERICAN WATER WORKS CO INC AWK	USD	10,400		2,600		131.220000	1,243,451.48	0.63 %
Equities		US0311621009	AMGEN INC AMGN	USD	20,000				266.600000	4,858,314.35	2.45 %
Equities		US0758871091	BECTON DICKINSON AND CO BDX	USD	9,000				235.690000	1,932,765.38	0.97 %
Equities		US09061G1013	BIOMARIN PHARMACEUTICAL INC BMRN	USD	17,400				89.740000	1,422,757.18	0.72 %
Equities		US1011371077	BOSTON SCIENTIFIC CORP BSX	USD	68,000		3,800		55.440000	3,435,006.83	1.73 %
Equities		US1101221083	BRISTOL-MYERS SQUIBB CO BMY	USD	90,000		2,000		48.720000	3,995,261.96	2.01 %
Equities		US1488061029	CATALENT INC CTLT	USD	40,600				39.570000	1,463,819.59	0.74 %
Equities		US03073E1055	CENCORA INC COR	USD	5,300		4,700		199.520000	963,513.44	0.49 %
Equities		US2166484020	COOPER COS INC/THE COO	USD	4,200				331.590000	1,268,954.90	0.64 %
Equities		US2358511028	DANAHER CORP DHR	USD	27,000				222.520000	5,474,296.13	2.76 %
Equities		US2521311074	DEXCOM INC DXCM	USD	24,500	4,500			116.180000	2,593,539.86	1.31 %
Equities		US28176E1082	EDWARDS LIFESCIENCES CORP EW	USD	27,500				67.430000	1,689,589.98	0.85 %
Equities		US5324571083	ELI LILLY & CO LLY	USD	26,000		1,000		591.860000	14,021,284.74	7.06 %
Equities		US3755581036	GILEAD SCIENCES INC GILD	USD	36,500				75.230000	2,501,954.44	1.26 %
Equities		US4052171000	HAIN CELESTIAL GROUP INC HAIN	USD	120,000	30,000			10.450000	1,142,596.81	0.58 %
Equities		US4448591028	HUMANA INC HUM	USD	6,500	2,000	1,500		482.410000	2,857,097.95	1.44 %
Equities		US45168D1046	IDEXX LABORATORIES INC IDXX	USD	5,300	1,300			466.740000	2,253,960.82	1.14 %
Equities		US46116X1019	INTRA-CELLULAR THERAPIES INC ITCI	USD	25,000	5,000	5,000		59.430000	1,353,758.54	0.68 %
Equities		US46120E6023	INTUITIVE SURGICAL INC ISRG	USD	17,000	4,000	3,000		310.760000	4,813,594.53	2.42 %
Equities		US4622601007	IOVANCE BIOTHERAPEUTICS INC IOVA	USD	280,000	110,000	20,000		5.680000	1,449,111.62	0.73 %
Equities		US46266C1053	IQVIA HOLDINGS INC IQV	USD	9,200				213.810000	1,792,302.51	0.90 %
Equities		IE00B4Q5ZN47	JAZZ PHARMACEUTICALS PLC JAZZ	USD	10,000		1,000		114.260000	1,041,093.39	0.52 %
Equities		US58933Y1055	MERCK & CO. INC. MRK	USD	85,600				101.130000	7,887,679.27	3.97 %
Equities		US60770K1079	MODERNA INC MRNA	USD	7,000				79.010000	503,936.22	0.25 %
Equities		US5534981064	MSA SAFETY INC MSA	USD	9,000		5,000		170.200000	1,395,717.54	0.70 %
Equities		US64125C1099	NEUROCRINE BIOSCIENCES INC NBIX	USD	12,000		2,000		113.540000	1,241,439.64	0.63 %
Equities		GB00BMVP7Y09	ROYALTY PHARMA PLC- CL A RPRX	USD	85,900	19,900			26.900000	2,105,430.52	1.06 %
Equities		IE00BFY8C754	STERIS PLC STE	USD	6,000				197.440000	1,079,398.63	0.54 %
Equities		US8636671013	STRYKER CORP SYK	USD	12,000		1,500		294.370000	3,218,624.15	1.62 %
Equities		CA8676EP1086	SUNOPTA INC STKL	USD	315,000	350,600	35,600		4.850000	1,392,027.33	0.70 %
Equities		US1255231003	THE CIGNA GROUP CI	USD	10,000		1,500		262.870000	2,395,170.84	1.21 %
Equities		US8835561023	THERMO FISHER SCIENTIFIC INC TMO	USD	15,500				492.920000	6,961,512.53	3.51 %
Equities		US91324P1021	UNITEDHEALTH GROUP INC UNH	USD	19,000				534.980000	9,261,612.76	4.66 %
Equities		US92532F1003	VERTEX PHARMACEUTICALS INC VRTX	USD	11,000		1,500		351.000000	3,517,995.44	1.77 %
Equities		US92847W1036	VITAL FARMS INC VITL	USD	120,000	124,900	4,900		12.840000	1,403,918.00	0.71 %
Equities		US9418481035	WATERS CORP WAT	USD	5,000		1,200		279.740000	1,274,441.91	0.64 %
Equities		US98956P1021	ZIMMER BIOMET HOLDINGS INC ZBH	USD	14,000		2,000		113.920000	1,453,193.62	0.73 %
Equities		US98978V1035	ZOETIS INC ZTS	USD	18,000		8,000		175.790000	2,883,116.17	1.45 %
Equities ADR		US09075V1026	BIONTECH SE-ADR BNTX	USD	10,000				99.250000	904,328.02	0.46 %
Total licensed securities admitted to trading on the official market or another regulated market										197,666,930.38	99.54 %
Total securities										197,666,930.38	99.54 %

Type of security	OGAW/§ 166	ISIN	Security title	Currency	Volume Units/Nom.	Purchases In period under review Units/Nom.	Sales	Pool-/ILB Factor	Price	Market value in EUR	Share of fund assets
Bank balances/liabilities				EUR						1,127,693.71	0.57 %
Total bank balances/liabilities										1,127,693.71	0.57 %
Accruals and deferrals											
Interest claims (on securities and bank balances)										9,229.82	0.00 %
Dividends receivable										132,802.14	0.07 %
Total accruals and deferrals										142,031.96	0.07 %
Other items											
Various fees										-362,353.81	-0.18 %
Total other items										-362,353.81	-0.18 %
Total fund assets										198,574,302.24	100.00 %

ISIN	Income class		Currency	Net asset value per unit	Units in circulation
AT0000714274	R	income-distributing	EUR	223.62	59,227.986
AT0000A1U651	RZ	income-distributing	EUR	136.19	39,314.967
AT0000714282	R	income-retaining	EUR	277.21	355,325.017
AT0000A1U644	RZ	income-retaining	EUR	147.80	234,734.296
AT0000A2XN33	SZ	income-retaining	EUR	99.13	10.000
AT0000A2R8Q2	I	full income-retaining (outside Austria)	EUR	109.31	10.000
AT0000712716	R	full income-retaining (outside Austria)	EUR	293.00	159,635.730

Exchange rates

Foreign currency assets were converted into EUR on the basis of the exchange rates applicable on Nov 29, 2023

Currency		Price (1 EUR =)
Australian Dollars	AUD	1.657500
Swiss Francs	CHF	0.960250
Danish Kroner	DKK	7.456000
British Pound	GBP	0.864350
Japanese Yen	JPY	161.766000
Swedish Krona	SEK	11.365000
US Dollars	USD	1.097500

Securities purchases and sales during the period under review not listed under the portfolio of assets:

Type of security	OGAW/§ 166	ISIN	Security title	Currency		Purchases Additions	Sales Disposals
Equities		AU000000CGC2	COSTA GROUP HOLDINGS LTD CGC	AUD			950,000
Equities		CH1243598427	SANDOZ GROUP AG SDZ	CHF		7,000	7,000
Equities		CH0012549785	SONOVA HOLDING AG-REG SOON	CHF			6,000
Equities		DK0060534915	NOVO NORDISK A/S-B NOVOB	DKK			56,000
Equities		FR0013154002	SARTORIUS STEDIM BIOTECH DIM	EUR			3,500
Equities		JP3351100007	SYSMEX CORP 6869	JPY			14,000
Equities		US0718131099	BAXTER INTERNATIONAL INC BAX	USD			29,500
Equities		US15135B1017	CENTENE CORP CNC	USD			22,000
Equities		US7611521078	RESMED INC RMD	USD			8,000
Equities		US8753722037	TANDEM DIABETES CARE INC TNDM	USD		2,300	40,000
Equities		US92338C1036	VERALTO CORP VLTO	USD		9,000	9,000
Subscription rights		FR001400GCH7	ESSILORLUXOTTICA SA-SCRIP 2261373D	EUR			10,000

Information on securities lending transactions and repurchase agreements

During the reporting period, no securities lending transactions were performed on behalf of the fund. Accordingly, the information concerning securities lending transactions which is stipulated in § 8 of the Austrian Securities Lending and Repurchase Agreement Ordinance and Art. 13 of Regulation (EU) No. 2015/2365 is not required.

During the reporting period, no repurchase agreements were concluded on behalf of the fund. Accordingly, the information concerning repurchase agreements which is stipulated in § 8 of the Austrian Securities Lending and Repurchase Agreement Ordinance and Art. 13 of Regulation (EU) No. 2015/2365 is not required.

Total return swaps and similar derivative instruments

A total return swap is a credit derivative instrument. Income and fluctuations in the value of the underlying financial instrument (underlying instrument or reference asset) are exchanged for fixed interest payments.

The fund did not enter into total return swaps or similar derivative instruments in the period under review.


Raiffeisen Kapitalanlage-Gesellschaft m.b.H. complies with the code of conduct for the Austrian investment fund industry 2012.

Vienna, 23 January 2024

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.



Mag. (FH) Dieter Aigner



Ing. Michal Kuštra



Mag. Hannes Cizek

Appendix

Imprint

Publisher:

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.

Mooslackengasse 12, A-1190 Vienna

Responsible for contents:

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.

Mooslackengasse 12, A-1190 Vienna

Copyright by publisher, dispatch location: Vienna

Raiffeisen Capital Management is the brand of:

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.

Raiffeisen Immobilien Kapitalanlage-Gesellschaft m.b.H.

Raiffeisen Salzburg Invest GmbH